ADC Therapeutics SA

21.04-0.1500-0.71%Vol 61.71K1Y Perf -56.32%
Jul 30th, 2021 16:00 DELAYED
BID20.85 ASK22.76
Open20.97 Previous Close21.19
Pre-Market- After-Market-
 - -  - -%
Target Price
47.25 
Analyst Rating
— — 0.00
Potential %
124.57 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.45B 
Earnings Rating
Price Range Ratio 52W %
3.09 
Earnings Date
3rd Aug 2021

Today's Price Range

20.8521.36

52W Range

20.0153.35

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-2.37%
1 Month
-13.59%
3 Months
-14.26%
6 Months
-26.36%
1 Year
-56.32%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ADCT21.04-0.1500-0.71
AAPL145.860.22000.15
GOOG2 704.42-26.3900-0.97
MSFT284.91-1.5900-0.55
XOM57.57-1.3600-2.31
WFC45.94-0.5600-1.20
JNJ172.200.02000.01
FB356.30-2.0200-0.56
GE12.95-0.3400-2.56
JPM151.78-1.2200-0.80
Earnings HistoryEstimateReportedSurprise %
Q01 2021-1.00-0.6733.00
Q04 2020-0.68-0.73-7.35
Q03 2020-0.77-0.2962.34
Q02 2020-0.96-0.7126.04
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date3rd Aug 2021
Estimated EPS Next Report-0.84
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume61.71K
Shares Outstanding68.89M
Trades Count700
Dollar Volume4.54M
Avg. Volume304.71K
Avg. Weekly Volume206.38K
Avg. Monthly Volume206.34K
Avg. Quarterly Volume275.09K

ADC Therapeutics SA (NYSE: ADCT) stock closed at 21.04 per share at the end of the most recent trading day (a -0.71% change compared to the prior day closing price) with a volume of 61.71K shares and market capitalization of 1.45B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 138 people. ADC Therapeutics SA CEO is .

The one-year performance of ADC Therapeutics SA stock is -56.32%, while year-to-date (YTD) performance is -34.27%. ADCT stock has a five-year performance of %. Its 52-week range is between 20.01 and 53.35, which gives ADCT stock a 52-week price range ratio of 3.09%

ADC Therapeutics SA currently has a PE ratio of -5.90, a price-to-book (PB) ratio of 5.66, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -55.09%, a ROC of -62.97% and a ROE of -85.36%. The company’s profit margin is -%, its EBITDA margin is -4 876.10%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from ADC Therapeutics SA, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.84 for the next earnings report. ADC Therapeutics SA’s next earnings report date is 03rd Aug 2021.

The consensus rating of Wall Street analysts for ADC Therapeutics SA is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for ADC Therapeutics SA stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ADC Therapeutics SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ADC Therapeutics SA has a Sell technical analysis rating based on Technical Indicators (ADX : 22.19, ATR14 : 1.08, CCI20 : -101.72, Chaikin Money Flow : -0.20, MACD : -0.68, Money Flow Index : 28.36, ROC : -8.20, RSI : 35.75, STOCH (14,3) : 22.76, STOCH RSI : 0.84, UO : 39.67, Williams %R : -77.24), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ADC Therapeutics SA in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

ADC Therapeutics SA

ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.

CEO:

Telephone: +41 216530200

Address: Route de la Corniche 3B, Epalinges 1066, , CH

Number of employees: 138

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

88%13%

Bearish Bullish

61%39%

Bearish Bullish

73%27%

News

Stocktwits